H.C. Wainwright lowered the firm’s price target on Prothena (PRTA) to $14 from $30 and keeps a Buy rating on the shares after the company announced that the AFFIRM-AL trial did not show statistical significance on the survival benefit, the primary endpoint for the study. The firm removed birtamimab from the current valuation but says PRX012 remains on track.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTA: